The Quieting: Ozempic, Desire, and the End of American Appetite

Thursday, May 28, 2026.

A man sits in his car staring at a fresh box of donuts with sprinkles.

Not resisting it.
Not negotiating with himself.
Not performing nutritional virtue for the invisible tribunal now governing American adulthood.

He simply no longer cares about it.

For years, the sprinkle donuts occupied psychic real estate.

Then one day it didn’t.

This is the real story hiding underneath the national obsession with Ozempic, Wegovy, and the expanding world of GLP-1 drugs.

The media keeps treating these medications as a weight-loss story.

But the more unsettling possibility is that they may actually be a desire story.

Because folks are reporting something stranger than reduced hunger.

They keep saying they want things less.

Less alcohol.
Less gambling.
Less compulsive shopping.
Less binge eating.
Less doomscrolling.
Less obsession.
Less emotional urgency.

Some even report diminished sexual desire, reduced emotional intensity, and a strange flattening of psychic noise itself.

• Researchers are now studying whether GLP-1 medications influence reward circuitry, addiction pathways, compulsive behavior, emotional salience, and dopamine-driven reinforcement systems.

Which means this may eventually become much larger than a pharmaceutical story.

This may become a civilization story.

America Is Built Around Managed Impulsivity

One of the awkward truths about modern capitalism is that enormous sectors of the economy quietly depend upon people remaining slightly overstimulated, slightly impulsive, slightly lonely, and continuously reachable by advertising.

The system does not merely tolerate dysregulation.

It monetizes it.

The food industry engineers hyper-palatable foods.
Social media engineers intermittent reinforcement loops.
Streaming platforms engineer binge behavior.
Online gambling platforms engineer compulsion.
Pornography platforms engineer novelty addiction.
News media engineers outrage dependency.

Meanwhile the average American carries a device capable of delivering stimulation, outrage, temptation, humiliation, comparison, loneliness, and consumption opportunities directly into the nervous system at nearly all hours of the day.

Then we wonder why people feel psychologically exhausted.

For decades, much of this exhaustion was framed as a moral problem.

Lack of discipline.
Weakness.
Poor self-control.
Personal failure.

But GLP-1 drugs are beginning to complicate that narrative in potentially profound ways.

Because many users do not describe the medications as producing heroic restraint.

They describe relief.

Relief from noise.
Relief from compulsive thinking.
Relief from incessant wanting.
Relief from the exhausting internal negotiations that govern so much of modern life.

Some people are not discovering self-control on these medications.

They are discovering what their minds sound like without constant internal bidding wars.

That distinction matters enormously.

The Fantasy Beneath The Drugs

Of course the appeal is obvious.

Many people are exhausted.

Exhausted by food noise.
Exhausted by advertising.
Exhausted by temptation.
Exhausted by optimization culture.
Exhausted by their phones.
Exhausted by self-monitoring.
Exhausted by the strange emotional fatigue of living inside systems specifically designed to capture and redirect attention.

The fantasy underlying GLP-1 drugs may not actually be thinness.

It may be peace.

Not perfection.
Not beauty.
Not self-improvement.

Just less noise.

And that possibility appears to touch something very deep in modern life.

The Pharmacology of Wanting

One of the most haunting lines in recent reporting on GLP-1 drugs asked:

“Where is the line between quieting a person’s destructive impulses and reshaping personality itself?”

Exactly.

Because modern identity culture increasingly treats desire as sacred.

If you crave something intensely enough, the culture assumes the craving must reveal something authentic about you.

Your appetites become identity.
Your obsessions become personality.
Your compulsions become self-expression.

But what happens if craving is less spiritual destiny than neurochemical weather?

That question destabilizes enormous portions of modern life.

Because many folks quietly organize themselves around appetite.

Food.
Ambition.
Sex.
Attention.
Shopping.
Status.
Validation.
Romantic pursuit.
Emotional intensity.

Entire personalities may partially consist of reward systems wearing expensive shoes.

And now medicine may be entering those systems directly.

The implications are difficult to overstate.

What If The Culture Runs On Craving?

The deeper issue here is not obesity.

It is economics.

A civilization organized around stimulation may not entirely know what to do with psychologically quieter people.

Imagine a culture in which millions of people suddenly:

• impulse buy less.

• drink less.

• binge less.

• gamble less.

• obsess less.

• scroll less.

• crave less.

Large portions of the American economy begin sweating immediately.

Because modern consumer culture increasingly depends upon engineered dissatisfaction.

You are too old.
Too unattractive.
Too lonely.
Too anxious.
Too behind.
Too ordinary.
Too unoptimized.

Then the culture sells you relief.

Products.
Subscriptions.
Convenience.
Distraction.
Aspiration.
Identity.
Stimulation.

The machine works by maintaining low-grade psychic agitation.

But GLP-1 drugs may be introducing something economically dangerous:

reduced urgency.

The drugs do not merely appear to only suppress hunger.

They may also suppress salience.

And salience — what the brain marks as important, urgent, emotionally rewarding, or worthy of pursuit — quietly governs enormous portions of human behavior.

Including capitalism.

Especially capitalism.

The Relationship Consequences May Be Enormous

This is where the story becomes especially strange.

Because desire is not merely biological.

It is attentional.

Long-term relationships are partially organized around salience systems:
Who captures attention?
Who generates anticipation?
Who regulates distress?
Who creates novelty?
Who feels emotionally rewarding?
Who generates neurological charge?

Therapists have long understood that many relationships operate as reinforcement systems.

Life partners become psychologically dependent upon:

• reassurance.

• conflict.

• validation.

• novelty.

• emotional intensity.

• romantic uncertainty.

• pursuit.

The nervous system itself learns relational cravings.

Researchers increasingly understand romantic attachment through overlapping systems involving dopamine, reward, reinforcement, anticipation, and emotional salience.

Helen Fisher’s research on romantic love identified motivational systems associated with attraction and pursuit, while Kent Berridge’s work distinguishes between “wanting” and “liking” as related but neurologically distinct systems.

Now imagine medications capable of altering those systems.

The implications become extraordinary.

Less compulsive texting.
Less obsessive longing.
Less emotional spiraling.
Possibly fewer addictive attachments.
Possibly less novelty-seeking behavior.
Possibly less affair intensity.

Or perhaps something sadder.

Less urgency altogether.

Therapists may eventually confront a strange new category of relationship dilemma:

“I still love you. I just no longer feel compulsively pulled toward anything.”

That sentence belongs less to marriage counseling than to speculative fiction.

Yet here we are.

Many affairs are not merely sexual events.

They are salience events.

One person begins generating more neurological charge than another.

GLP-1 medications may eventually complicate that equation in ways nobody yet fully understands.

The science remains early.
The evidence remains preliminary.

But culturally, the implications are already humming underneath the conversation.

The Strange Sadness Of Quiet

What gives this topic emotional depth is that many partners sound simultaneously relieved and unsettled.

Some describe liberation.
Others describe flattening.
A few sound almost bereaved.

As though some loud and unruly part of themselves has quietly left the building.

And perhaps this reveals something painful about modern life.

Many life partners have lived inside overstimulated nervous systems for so long that emotional quiet initially feels unfamiliar — even frightening.

The philosopher Byung-Chul Han has argued that modern societies increasingly produce exhausted selves trapped inside endless cycles of performance, stimulation, and achievement.

Psychiatrist Anna Lembke similarly describes modern life as a state of chronic dopamine overload, where escalating stimulation gradually diminishes satisfaction itself.

GLP-1 drugs may represent the first mass-market interruption of that cycle.

Not through religion.
Not through meditation.
Not through philosophy.
Not through discipline.

Through pharmacology.

Which is perhaps the most American development imaginable.

• The birth control pill separated sex from reproduction.

• Social media separated attention from physical presence.

• GLP-1 drugs may partially separate desire from compulsion.

And if that is true, we may be entering one of the strangest psychological transitions of modern life.

Because somewhere tonight, millions of people will sit quietly in front of foods, substances, purchases, apps, fantasies, and compulsions that once dominated enormous portions of their inner lives.

Some will feel relieved.

Some will feel frightened.

Some may quietly wonder whether they have lost part of themselves.

Modern culture spent decades teaching people to build identities around appetite:
what they wanted.
what they chased.
what they consumed.
what they could not stop thinking about.

And now millions of people are discovering what happens when the wanting quiets.

The question is no longer whether these medications change appetite.

The question is whether modern life knows who we are without it.

FAQ

Are scientists actually studying GLP-1 drugs for addiction and mental health?

Yes. Researchers are actively investigating whether GLP-1 medications influence addiction, compulsive behavior, reward processing, emotional regulation, and psychiatric symptoms. Studies involving alcohol-use disorder, nicotine dependence, gambling, binge eating, and other compulsive behaviors are currently underway.

Do GLP-1 drugs directly affect the brain?

Scientists are still studying the exact mechanisms involved. GLP-1 receptors exist in brain regions associated with appetite, reward, emotional processing, and stress regulation. Researchers suspect the medications may influence both metabolic and neurological systems simultaneously.

Why do some people report emotional flattening on Ozempic or Wegovy?

Some users describe reduced emotional intensity, lower motivation, diminished pleasure, or reduced sexual desire while taking GLP-1 medications. Researchers are currently investigating whether changes in reward circuitry or salience processing may contribute to these experiences.

Could GLP-1 medications affect relationships?

Potentially. Since romantic attachment and desire are closely tied to reward, novelty, emotional salience, and reinforcement systems, changes in these systems could theoretically influence relationship dynamics, attraction patterns, and emotional intensity.

Final Thoughts

Perhaps the strangest realization emerging from the GLP-1 era is this:

many folks may not have been failing at self-control.

They may simply have been living inside reward systems no human nervous system evolved sufficiently to resist.

And now millions of life partners and families are discovering what it feels like when the volume lowers.

Not happiness.

Not enlightenment.

Just less wanting.

Which, in modern America, may qualify as a radical experience.

Be Well, Stay Kind, and Godspeed.

REFERENCES:

Berridge, K. C., & Robinson, T. E. (2016). Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist, 71(8), 670–679. https://doi.org/10.1037/amp0000059

Fisher, H. E. (2004). Why we love: The nature and chemistry of romantic love. Henry Holt.

Han, B.-C. (2015). The burnout society. Stanford University Press.

Hernandez, N. S., Ige, K. Y., Mietlicki-Baase, E. G., Molina-Castro, G. C., Turner, C. A., Hayes, M. R., & Schmidt, H. D. (2018). Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. Neuropsychopharmacology, 43(10), 2000–2008. https://doi.org/10.1038/s41386-018-0010-0

Lembke, A. (2021). Dopamine nation: Finding balance in the age of indulgence. Dutton.

Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine, 374(4), 363–371. https://doi.org/10.1056/NEJMra1511480

Volkow, N. D., Wang, G.-J., Fowler, J. S., Tomasi, D., & Baler, R. (2012). Food and drug reward: Overlapping circuits in human obesity and addiction. Current Topics in Behavioral Neurosciences, 11, 1–24. https://doi.org/10.1007/7854_2011_169

Washington Post staff. (2026, May 28). Ozempic may be reshaping the brain, scientists say. The Washington Post.